



The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 25 September 2001
CPMP/2973/01

PRESS RELEASE

Committee for Proprietary Medicinal Products Meeting of 18 to 20 September 2001

No opinions on initial marketing authorisation applications were adopted at this meeting.

The Committee further discussed its scientific review of cardiovascular risks of 'third generation' combined oral contraceptives. Communication on the outcome is foreseen for October 2001.

The CPMP initiated a Community-level review on the risk-benefit of cerivastatin containing medicinal products authorised under the mutual recognition procedure, following a referral by Portugal under Article 15a of Council Directive 75/319/EEC.

A more detailed CPMP meeting report will be made available later this week, including details from the MRFG meeting of 17 September 2001.

--ENDS--

For further information, please contact:

Noël Wathion
Head of Unit, Post-authorisation evaluation of medicinal products
Tel. (44-20) 74 18 85 92

Martin Harvey
EMA press officer
Tel. (44-20) 74 18 84 27